Skip to content
France
-
Axoltis Pharma secures USD20.9 million in series A funding to advance ALS drug development
The total USD20.9 million funding will be divided into two tranches, with the release of the second contingent on outcomes from the ongoing ‘SEALS’ phase 2 clinical trial.